Data Sheet 3_A Bayesian network meta-analysis: evaluating the efficacy and safety of targe

A 2026 Bayesian network meta-analysis of 9 randomized controlled trials involving 1,760 patients with metastatic or advanced radioiodine-refractory differentiated thyroid cancer. The analysis, authored by Pin Wang and shared on figshare, evaluates the efficacy and safety of targeted therapies, comparing outcomes like progression-free survival, overall survival, and adverse events.

Use Cases

• Ranking the efficacy of targeted therapies like lenvatinib and apatinib based on progression-free survival hazard ratios.
• Comparing the safety profiles of different treatments based on the reported grade ≥3 adverse events.
• Investigating time-dependent efficacy patterns of tyrosine kinase inhibitors for radioiodine-refractory thyroid cancer.
• Validating or informing clinical trial design for advanced thyroid cancer treatments based on network meta-analysis results.

Strengths

• Analysis is based on 9 randomized controlled trials, a standard for clinical evidence.
• Includes data from 1,760 patients, providing a substantial sample for the meta-analysis.
• Uses Bayesian statistical methods and reports results with hazard ratios, odds ratios, and SUCRA ranking scores.
• Has a registered systematic review protocol (CRD420251089713).

Limitations

• The dataset is very small (22.3 KB), suggesting it contains summary results rather than patient-level data.
• Row count and column-level documentation are unknown; field semantics must be inferred from the description.
• Data may reflect the specific inclusion criteria and time period of the underlying clinical trials.

Provenance

Source

Pin Wang via figshare.

Collection Method

Systematic search of six electronic databases and Bayesian network meta-analysis of identified randomized controlled trials.

Freshness

Last updated 2026-03-18 07:35:14.